FDA Orders Vision Loss Warning to Ozempic, GLP-1 Drug Labels
The FDA is requiring new warnings about rare, potentially permanent vision loss associated with Ozempic and other GLP-1 medications. The order has raised important questions about NAION risks, patient safety, and the potential impact on ongoing lawsuits.










